Former CooperVision Leader Tom Bender Joins MediPrint Ophthalmics as Strategic Advisor

2024-02-13

高管变更临床2期

SAN DIEGO--(BUSINESS WIRE)--MediPrint Ophthalmics, a clinical stage ophthalmic company focused on transforming the delivery of ophthalmic pharmaceuticals, today proudly announced the appointment of Thomas Bender as a strategic advisor. Mr. Bender, former President, CEO, and Chairman of CooperVision and The Cooper Companies, will lend his vast expertise to the company’s management and board of directors in developing its proprietary technology for delivery of ophthalmic drugs via contact lenses.

'Tom Bender\'s appointment marks a defining moment for our company. His exceptional leadership transformed CooperVision into a global market leader, and we anticipate his insights will greatly progress our strategic initiatives and operational excellence.'

Mr. Praful Doshi, CEO and Founder of MediPrint Ophthalmics, welcomed the new addition, stating, "Tom Bender's appointment marks a defining moment for our company. His exceptional leadership transformed CooperVision into a global market leader, and we anticipate his insights will greatly progress our strategic initiatives and operational excellence."

Mr. Bender served as CEO of CooperVision from 1991 until his retirement as CEO in 2007, continuing as Chairman until 2021. Under Mr. Bender’s leadership, CooperVision grew from a $20 million operation to a multi-billion-dollar leader in the contact lens industry. Prior to his tenure at CooperVision, Mr. Bender was an executive at Allergan for 25 years, leading up to his role as President of Herbert Labs from 1986 to 1991.

Mr. Bender’s joining of MediPrint Ophthalmics is timely as the company advances its leading product in delivery of Glaucoma medication to pivotal Phase III and help improve lives of glaucoma patients. Welcome Mr. Bender.

MediPrint Ophthalmics stands at the forefront of Ophthalmic innovation as a clinical-stage platform technology company revolutionizing ocular drug delivery. With a steadfast commitment to enhancing vision, our flagship product involves proprietary 3D printing of bimatoprost drug onto contact lenses, delivering sustained relief to patients battling Glaucoma or Ocular Hypertension. Affecting over 100 million individuals globally and more than 8 million in the US alone, Glaucoma and Ocular Hypertension are primarily treated by ophthalmic drops representing significant unmet needs. MediPrint has successfully completed its Phase II clinical study. Our robust pipeline is focused on products designed to enhance comfort, alleviate dry eye, and combat various ocular diseases. Based in San Diego, California, MediPrint is not just pioneering change; we are defining the future of ocular drug delivery.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构